Survival Estimates for Cancer Treatment Delay During COVID-19 Pandemic

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, OCTOBER 29, 2020

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2020.5403?guestAccessKey=0e57d646-2b8d-43fa-83c9-8f8ed73b2e0a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102920

 

What The Study Did: This decision analytical model uses a web-based application and data from the Surveillance, Epidemiology and End Results (SEER) program to quantitatively integrate mortality estimates and to examine the impact of cancer treatment delay among adults with cancer during the COVID-19 pandemic.

Authors: Matthew J. Schipper, Ph.D., of the University of Michigan in Ann Arbor, is the corresponding author.

 

(doi:10.1001/jamaoncol.2020.5403)

Editor’s Note: The article includes conflicts of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.